tbuckley/cabot-search huggingface dataset:
Screening children at immunisation visits can identify familial hypercholesterolaemia
Authors: Susan Mayor
Journal: BMJ (2016)

Screening children for familial hypercholesterolaemia (FH) when they see their GP for routine childhood immunisations can identify those at high risk for inherited premature cardiovascular disease, as well as parents at risk, a UK primary care study has found.1

FH is a relatively common genetic disorder affecting around one in 250 people. It is associated with raised low density lipoprotein (LDL) cholesterol throughout life, and premature atherosclerotic cardiovascular disease occurs in around one in four women and around half of men with heterozygous FH if they are not treated with statins.

Identifying young …
TCT-634 Feasibility and Efficacy of Transapical Implantation of a Novel Transcatheter Mitral Bio-Prosthesis in a Pig Model
Authors: Yanping Cheng, Torsten Vahl, Veronica Woen, Adrienne Meyers, Sulli Popilskis, Patricia Mount, Andres Valencia, Amanda Corn, Gerard Conditt, Robert Swain, Greg Kaluza, Genghua Yi
Journal: Journal of the American College of Cardiology (2016)
Treatment-Free Remission (TFR) Eligibility in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) and Residual Disease on Long-Term Imatinib (IM) Who Switched to Second-Line Nilotinib (NIL)
Authors: Timothy P. Hughes, Francisco Cervantes, Nelson Spector, Brian Leber, Susan Branford, Tara A. Glynos, Sandip Acharya, Darshan Dalal, Jeffrey H. Lipton
Journal: Blood (2015)
TCT-610 Three-dimensional rotational angiography in the guidance of percutaneous pulmonary valve implantation: does it help preventing coronary compression?
Authors: Bart Driesen, Han Dronkert, Gertjan Sieswerda, Folkert Meijboom, Mirella Molenschot, Pieter Doevendans, Gregor Krings, Michiel Voskuil
Journal: Journal of the American College of Cardiology (2016)
The Bone Marrow-Derived Mesenchymal Cells Were Injured By Iron Overload through Catalyzing the Production of Reactive Oxidative Stress in Mice
Authors: Yuchen Zhang, Mingfeng Zhao, Deguan Li, Xiaoli Cao, Jie Chen, Juan Mu, Qing Li, Xia Xiao, Xiao Chai, Aimin Meng
Journal: Blood (2014)
TCT-252 The incidence, determinants and outcomes of coronary perforation during percutaneous coronary intervention in the United Kingdom between 2006–2013: an analysis of 527,121 cases from the British Cardiovascular Intervention Society database
Authors: None tim kinnaird, Chun Shing Kwok, None evan kontopantelis, Ossei-Gerning Nick, Peter Ludman, Mark de Belder, Richard Anthony Anderson, Mamas Mamas
Journal: Journal of the American College of Cardiology (2016)
Disclosure of sexual orientation in men who have sex with men in China: a cross-sectional survey
Authors: Weiming Tang, Jessica Mao, Songyuan Tang, Chuncheng Liu, Katie Mollan, Terrence Wong, Ye Zhang, Michael Hudgens, Yilu Qin, Baoli Ma, Meizhen Liao, Bin Yang, Wei Ma, Dianmin Kang, Chongyi Wei, Joseph D Tucker
Journal: The Lancet (2016)
TCT-456 Direct Implantation of Rapamycin-Eluting Stents with Bioresorbable Drug Carrier Technology Utilizing the Svelte Coronary Stent-on-a-Wire: 2-Year Follow-Up of the Randomized, Controlled DIRECT II Study
Authors: Stefan Verheye, Pieter Stella, didier CARRIE, Ahmed Khattab, ton slagboom, Jozef Bartunek
Journal: Journal of the American College of Cardiology (2016)
Phase I/II study of a hybrid schedule of flavopiridol in relapsed/refractory mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL)
Authors: K. Tay, G. Shapiro, M. Disinski, L. R. Chirieac, S. Pittaluga, E. S. Jaffe, J. E. Janik, A. Wiestner, W. H. Wilson, K. Dunleavy
Journal: Journal of Clinical Oncology (2009)

8563 Background: Continuous infusion and bolus schedules of flavopiridol in MCL have yielded disappointing results. However, a pharmacologically derived hybrid schedule of administration is effective in refractory, genetically high-risk CLL, though life-threatening tumor lysis syndrome (TLS) may occur in patients with very high lymphocyte counts. Because flavopiridol decreases cyclin D1 and mcl-1 and induces apoptosis in MCL cells, is significantly toxic for cell lines derived from the activated B-cell-like type of DLBCL (OCI-Ly3) and down-regulates NF-kappa B, we investigated the hybrid schedule in MCL and DLBCL. Methods: Flavopiridol was administered as a 30-minute bolus (mg/m2) followed by a 4-hour continuous infusion (mg/m2), weekly for 4 doses every 6 weeks. Separate escalation rules applied to cycle 1 week 1 (C1W1) and all other weeks of treatment. Dose levels on C1W1 were DL1: 25/25 (4 pts); DL2: 30/30 (10 pts) and DL3: 30/50 (6 pts). Dose escalation on subsequent weeks was not possible due to toxicity and all pts received 30/50. All patients received TLS prophylaxis. Paired biopsy samples obtained before and after the first dose were analyzed for cdk targets. Results: Patient (n=20) characteristics: median age: 59 (r 24–80); male 15 (75%); median prior regimens 2 (r 1–6). 10 had MCL and 10 had DLBCL. Responses were PR in 2 (1 MCL; 1 DLBCL) pts (10%); SD in 5 (25%); and PD in 13 (65%). DLTs were TLS and severe vomiting/diarrhea in 2 pts at DL3. The MTD and phase II dose has not yet been defined. Other toxicities were grade 4 ANC (10 pts) requiring prophylactic G-CSF, TLS (1 pt) and bowel perforation (1 pt). Decreased Rb staining at the S807/811 phospho-site was noted in 8 of 9 paired samples analyzed (r 20–75%; p = 0.027) and at the S780 site in 7 of 8 paired samples (r 38–91%; p = 0.00016), suggestive of G1 cdk inhibition. In 1 sample in which p53 was detected, there was an increase post-treatment, suggestive of cdk9 inhibition. Conclusions: The hybrid schedule of flavopiridol has modest activity in relapsed MCL and DLBCL. TLS occurred infrequently and was reversible. DLTs were TLS and gastrointestinal toxicity. Accrual continues. Analysis of cell cycle and transcriptional cdk targets is ongoing. No significant financial relationships to disclose.
TCT-270 Long-term clinical outcomes of patients with coronary chronic total occlusion treated with percutaneous coronary intervention versus medical therapy according to presence of diabetes mellitus
Authors: Ki Hong Choi, Jeong Hoon Yang, Seung-Hyuk Choi, Young Bin Song, Joo-Yong Hahn, Jin Ho Choi, Hyeon-Cheol Gwon, Sang Hoon Lee
Journal: Journal of the American College of Cardiology (2016)
TCT-363 Patient Characteristics Influencing Physician Selection of Radial vs. Femoral Access in patients presenting emergently with ST-Elevation Myocardial Infarction
Authors: Jimmy Yee, James Higgins, Vishesh Kumar, Amornpol (Song) Anuwatworn, Shenjing Li, Alexander Pham, Julia Stys, Terezia Petraskova, Paul Thompson, Adam Stys, Marian Petrasko, Tomasz Stys
Journal: Journal of the American College of Cardiology (2016)
Mitochondrial DNA Minisatellites Showed Higher Informativeness and Sensitivity Than the Nuclear DNA Markers for the Quantitative Determination of Chimerism After Allogeneic Stem Cell Transplantation,
Authors: Hye Ran Kim, Eun-Jeong Won, Hyun-Jung Choi, Hwan-Young Kim, James Moon, Jong-Hee Shin, Soon-Pal Suh, Dong-Wook Ryang, Myung-Geun Shin
Journal: Blood (2011)
Overexpression of exogenous kidney-specific Ngal attenuates progressive cyst development and prolongs lifespan in a murine model of polycystic kidney disease
Authors: Ellian Wang, Yuan-Yow Chiou, Wen-Yih Jeng, Hsiu-Kuan Lin, Hsi-Hui Lin, Hsian-Jean Chin, Chi-Kuang Leo Wang, Shang-Shiuan Yu, Shih-Chieh Tsai, Chih-Ying Chiang, Po-Hao Cheng, Hong-Jie Lin, Si-Tse Jiang, Sou-Tyau Chiu, Hsiu Mei Hsieh-Li
Journal: Kidney International (2016)
Water Soluble Melanin Derivatives for Dynamic Contrast Enhanced Photoacoustic Imaging of Tumor Vasculature and Response to Antiangiogenic Therapy
Authors: Dario L. Longo, Rachele Stefania, Chiara Callari, Francesco De Rose, Riccardo Rolle, Laura Conti, Lorena Consolino, Francesca Arena, Silvio Aime
Journal: Advanced Healthcare Materials (2016)

A dynamic contrast enhanced (DCE) approach for tumor photoacoustic (PA) imaging is described. Novel water soluble melanin-based derivatives are synthesized that exhibit good PA properties, stability, safety and accumulation in tumor bearing mice. This melanin derivative is capable to characterize tumor vasculature and to monitor vessel permeability changes upon antiangiogenic treatment. DCE-PA imaging can assess functional response to cancer treatments.
Tau Prion Strains Dictate Patterns of Cell Pathology, Progression Rate, and Regional Vulnerability In Vivo
Authors: Sarah K. Kaufman, David W. Sanders, Talitha L. Thomas, Allison J. Ruchinskas, Jaime Vaquer-Alicea, Apurwa M. Sharma, Timothy M. Miller, Marc I. Diamond
Journal: Neuron (2016)
PS01.51: The Impact of PET Staging and Molecular Profiling on the Radiotherapy Outcomes of Primary Lung Adenocarcinoma
Authors: Brendan Seng Hup Chia, Kevin Lee Min Chua, W.L. Ng, S.P. Yap, A. Thiagarajan, T.R. Siow, S.P.C. Yip, Kam Weng Fong
Journal: Journal of Thoracic Oncology (2016)
TCT-811 Next Generation Sequencing in Patients with Hypertrophic Cardiomyopathy Undergoing Alcohol Septal Ablation
Authors: Pavol Tomasov, Patricia Norambuena, Denisa Jahnlova, Jiri Bonaventura, Nikola Ptakova, Milan Macek, Milan Macek, Josef Veselka
Journal: Journal of the American College of Cardiology (2016)
TCT-498 Lower mortality in patients with vasospastic angina who receive statin therapy: Data from the Asan Vasospastic Angina Registry
Authors: Cheol Hyun Lee, Osung Kwon, Ungjeong Do, Jung Ae Hong, Kyusup Lee, Min Soo Cho, JAESEOK BAE, Do-yoon Kang, Se Hun Kang, Pil Hyung Lee, Sung-Han Yoon, Jung-Min Ahn, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2016)
No Difference in Risk of Recurrent Venous Thrombosis between Men and Women. Results from a Family Cohort Study in 3356 Subjects.
Authors: Willem M. Lijfering, Michiel Coppens, Nic J.G.M. Veeger, Saskia Middeldorp, Karly Hamulyak, Martin H. Prins, Harry R. Buller, Jan van der Meer
Journal: Blood (2007)
Measurement of quality of care for adjuvant chemotherapy of colorectal cancer
Authors: M. Morse, R. Prosnitz, C. Mantyh, D. Fisher, G. Samsa, D. McCrory, K. Cline, R. Gray, M. Patwardhan
Journal: Journal of Clinical Oncology (2006)

6071 Background: Although adjuvant chemotherapy (CT) is a crucial component of the therapy for stage III colon cancer and stage II and III rectal cancer patients, little is known about how best to measure whether quality care is being delivered. We sought to provide policy-makers and stake-holders with an inventory of the available measures and their usefulness. Methods: The MEDLINE and Cochrane databases were searched for all publications which might contain quality measures (QMs) pertaining to the diagnosis and treatment of patients with colorectal cancer (CRC). Our analysis was confined to QMs pertaining to adjuvant CT for CRC, based on US data, and published after 1990. Identified QMs were quantitatively rated based on the concepts of importance/usability, scientific acceptability, and validity or how well they had been tested. Results: 3,429 abstracts were reviewed, of which 843 articles underwent full text evaluation. Ultimately 74 articles met the established inclusion criteria for containing QMs, 32 of which pertained to adjuvant CT. These 32 articles contained 10 QMs, 8 of which had major flaws limiting their applicability. The two most ideal measures are presented in the table . Among the reasons some measures did not rate highly was the failure to utilize standard staging definitions or reliance on administrative inpatient databases, which do not account for chemotherapy administered on an out-patient basis. Conclusions: Very few measures of the quality of adjuvant CT for CRC have been published to date and fewer rate highly with regard to the concepts of importance/usability, scientific acceptability, and validity. Future research should focus on refining existing QMs and on developing new QMs which target important leverage points with respect to the provision of adjuvant therapy for CRC. [Table: see text] [Table: see text]
Prolonged colonisation with Escherichia coli O25:ST131 versus other extended-spectrum beta-lactamase-producing E. coli in a long-term care facility with high endemic level of rectal colonisation, the Netherlands, 2013 to 2014
Authors: Ilse Overdevest, Manon Haverkate, Jacobien Veenemans, Yvonne Hendriks, Carlo Verhulst, Ans Mulders, Willemijn Couprie, Martin Bootsma, James Johnson, Jan Kluytmans
Journal: Eurosurveillance (2016)

The extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli clone ST131 (ESBL-ST131) has spread in healthcare settings worldwide. The reasons for its successful spread are unknown, but might include more effective transmission and/or longer persistence. We evaluated the colonisation dynamics of ESBL-producing E. coli (ESBL-EC), including ESBL-ST131, in a long-term care facility (LTCF) with an unusually high prevalence of rectal ESBL-EC colonisation. During a 14-month period, rectal or faecal samples were obtained from 296 residents during six repetitive prevalence surveys, using ESBL-selective culture. Transmission rates, reproduction numbers, and durations of colonisation were compared for ESBL-ST131 vs other ESBL-EC. Furthermore, the likely time required for ESBL-ST131 to disappear from the LTCF was estimated. Over time, the endemic level of ESBL-ST131 remained elevated whereas other ESBL-EC returned to low-level prevalence, despite comparable transmission rates. Survival analysis showed a half-life of 13 months for ESBL-ST131 carriage, vs two to three months for other ESBL-EC (p &lt; 0.001). Per-admission reproduction numbers were 0.66 for ESBL-ST131 vs 0.56 for other ESBL-EC, predicting a mean time of three to four years for ESBL-ST131 to disappear from the LTCF under current conditions. Transmission rates were comparable for ESBL-ST131 vs other ESBL-EC. Prolonged rectal carriage explained the persistence of ESBL-ST131 in the LTCF.
Colorado’s bid to create first single payer system in US faces uphill fight
Authors: Michael McCarthy
Journal: BMJ (2016)

A measure on the 8 November ballot in Colorado that would create the first single payer healthcare system in the United States faces apparently insurmountable opposition, as polls indicate that about 60% of voters oppose the law and that only about 30% approve.

The Colorado Creation of ColoradoCare System Initiative, also known as amendment 69, would amend the state constitution to establish a healthcare payment system that would finance universal healthcare for all Colorado residents.

State initiatives allow voters to bypass their legislators and place measures on election ballots through a signature gathering process. If a majority of voters support the initiative, the measure becomes law.

Proponents, pointing to efficiencies …
TCT-731 Transcatheter Aortic Valve Replacement versus Surgical Valve Replacement for low to intermediate surgical-risk patients: A meta-analysis of 5,346 patients
Authors: Aakash Garg, Abhishek Sharma, Sahil Agrawal, Deepti Virmani, John Kostis, Dinesh Singal
Journal: Journal of the American College of Cardiology (2016)
Confounding by Indication in Clinical Research
Authors: Demetrios N. Kyriacou, Roger J. Lewis
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
TCT-735 CoreValve device implantation ‘true cover index’ predicts mid-term aortic regurgitation; a novel index
Authors: Manolis Vavuranakis, Konstantinos Kalogeras, MARIA LAVDA, ANGELOS-MICHAIL KOLOKATHIS, Theodoros Papaioannou, Myrsini Stasinopoulou, Dimitrios Vrachatis, None carmen moldovan, Maria Kariori, Evelina Bei, Gerasimos Siasos, Sophia Vaina, Evangelos Oikonomou, Dimitrios Tousoulis
Journal: Journal of the American College of Cardiology (2016)
Is it time to revisit the role of ultrasound in rheumatoid arthritis management?
Authors: MA D'Agostino, M Boers, R J Wakefield, P Emery, P G Conaghan
Journal: Annals of the Rheumatic Diseases (2016)

For over a decade, a large number of studies have highlighted the benefits of ultrasound (US) in the diagnosis and management of rheumatic diseases, especially rheumatoid arthritis (RA). However, its benefits in routine practice have been less studied and trials examining US as part of various clinical strategies are just emerging, with recent randomised trials examining the added value of US in tight-control paradigms. The conclusions of these trials have raised questions on the role of US in RA management. This Viewpoint analyses the recent studies, and discusses potential limitations in study designs as well as the methodological challenges of assessing the added value of an imaging technique.
Reply
Authors: Sarah Sheibani, Loren Laine
Journal: Hepatology (2016)

This article has been contributed to by U.S. Government employees and their work is in the public domain in the USA. Potential conflict of interest: Nothing to report. Reply: These letters demonstrate that health care providers may make different clinical decisions even when considering the same data. Our study showed that more patients in the 1‐week ligation interval group, compared to the 2‐week group, met the primary endpoint of variceal eradication at 4 weeks (82% vs. 51%) and that variceal eradication occurred more rapidly in the 1‐week group (18 vs. 31 days) without an increased number of endoscopies.1 Both letters disagree with 1‐week intervals because no benefit was shown in rebleeding. We agree the ultimate goal of variceal ligation is to decrease rebleeding. However, given that rebleeding rates were low in this study, a much larger, multicenter study is needed to determine whether a significant difference in rebleeding exists. Given that most recurrent variceal bleeding occurs within 6 weeks,2 early eradication of varices potentially could be associated with a decrease in variceal bleeding in larger studies. Both letters also cite small, nonsignificant differences in secondary endpoints in an attempt to support their opinions, and both raise the issue of ligation‐induced ulcers. Dr. Lo mentioned that the number of ligation‐induced ulcers was not shown in our study and reports his results showing higher rates of ulcers in patients treated with ligation at 2‐week, as compared to 4‐week, intervals.3 We do not believe that the endoscopic finding of ligation‐induced ulcers without clinical adverse events is a meaningful outcome. Furthermore, ligation‐induced ulcers in Dr. Lo's study cannot be appropriately assessed because of unequal measurement of this outcome in the study groups: Patients undergoing endoscopy 2 weeks after ligation will have more ulcers identified than those undergoing endoscopy 4 weeks after ligation. Our study showed no significant difference between the 1‐ and 2‐week groups in the proportion of patients who developed ligation‐induced ulcer bleeding, dysphagia, odynophagia, or chest pain. The mean number of bands placed to achieve eradication was also comparable in the 1‐ and 2‐week groups (8.7 vs. 8.2). Overall, our study demonstrated that when performing variceal ligation for the prevention of esophageal variceal bleeding, 1‐week, compared to 2‐week, intervals led to more‐rapid eradication of varices without an increase in complications or an improvement in rebleeding. Until larger studies provide more information, we believe that the available evidence allows a range of choices regarding the interval for endoscopic ligation. Physicians and patients can use our results along with other available data to make individualized decisions, taking into account their preferences as well as local logistics and resources.
Deferasirox Inhibit Doxorubicin-Induced Reactive Oxygen Species Generation in Both Acute Myeloid Leukemia and Normal Heart Cell While Maintain the Cytotoxicity of Doxorubicin Only on Acute Myeloid Leukemia
Authors: Su-Peng Yeh, Yu-Chien Chang, Wen-Jyi Lo, Min-Lih Huang, Yang-Sheng Yang, Pei Ching Hsiao, Dian-Kun Li
Journal: Blood (2012)
Regression of pre-established intracranial tumor growth by ON 01910.Na, a selective anticancer agent currently in phase I trials
Authors: C. S. Gondi, N. Kandhukuri, N. Yanamandra, M. Reddy, E. Reddy, J. S. Rao
Journal: Journal of Clinical Oncology (2006)

1576 Background: Despite considerable progress in the treatment modalities used for brain tumors (surgery, radiation therapy and chemotherapy), local recurrence continues to be an important reason for treatment failure. Since multiple regulatory pathways are defective in these tumor cells, novel approaches must tackle more than one mechanism involved in the process of neoplasia. One approach is to effectively combine anti-tumor agents with anti-angiogenic assault. Onconova has developed agents that fit this profile. ON 01910.Na, an injectable product now undergoing Phase I studies at multiple centers, is a potent inhibitor of mitotic progression. It arrests cancer cells in mitosis by depleting cells of CDC25c and efficiently induces apoptosis in the irreversibly arrested cells. Methods: Here, we have evaluated the invasiveness, angiogenesis, and tumorigenicity of glioblastoma cells in both in vitro and in vivo models after treatment with ON 01910. Results: SNB19 cells treated with ON 01910 were significantly inhibited in migration, invasion, and angiogenesis in in vitro models compared to the control group. After treatment with ON 01910, SNB19 cells showed decreased levels of MMPs, uPA, pAKT and PI3 kinase levels compared to controls. Significantly increased levels of PARP, caspase 3 and caspase 9 were also shown. In addition, there was complete regression of pre-established intracranial tumor growth and angiogenesis in in vivo models. The effect was more significant in relation to invasion, angiogenesis and tumor growth when compared to other drugs such as BCNU and Gleevec. Toxicology studies, where ON 01910 was administered systemically or directly into the brain, demonstrate the safey and tolerability of this agent in animals and ongoing Phase I studies indicate that the agent is well-tolerated at dose levels generating pharmacologically relevant concentration of the drug in circulation. Conclusions: These studies validate the potential usefulness of this compound as a novel therapeutic agent for human glioblastoma. [Table: see text]
TCT-176 Clinical Outcomes of Patients Receiving Pre-treatment with Dual Anti-platelet Therapy in ST-Elevation Myocardial Infarction
Authors: Matias Yudi, Omar Farouque, Andrew Ajani, Angela Brennan, Nick Andrianopoulos, Stephen Duffy, Melanie Freeman, Thomas Yip, Chris Reid, David Clark
Journal: Journal of the American College of Cardiology (2016)